Fosifloxuridine nafalbenamide (Synonyms: NUC-3373) |
Katalog-Nr.GC62645 |
Fosifloxuridinnafalbenamid (NUC-3373), ein Pyrimidin-Nukleotid-Analogon, ist ein Thymidylat-Synthase-Hemmer. Fosifloxuridinnafalbenamid hat AntikrebsaktivitÄt. Fosifloxuridinnafalbenamid hat das Potenzial, eine Immunantwort des Wirts hervorzurufen und die Immuntherapie zu verbessern.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1332837-31-6
Sample solution is provided at 25 µL, 10mM.
Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunotherapy[1][2].
Fosifloxuridine nafalbenamide induces the release of damage-associated molecular patterns (DAMPs), with increased expression of calreticulin (CRT) at the cell surface and concomitant loss of nuclear nuclear high mobility group box protein 1 (HMGB1)[1].
Fosifloxuridine nafalbenamide exhibits anti-cancer activity in HT-29 nude mouse xenograft models[2].
[1]. Fiona G. McKissock, et al. Abstract 1848: NUC-3373 induces ER stress and the release of damage associated molecular patterns in colorectal cancer cells. Cancer Res August 15 2020 (80) (16 Supplement) 1848.
[2]. Essam A. Ghazaly, et al. Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survival. Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) B46.
Average Rating: 5
(Based on Reviews and 18 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *